Experimental and Clinical Pharmacopsychology, University Hospital of Psychiatry Zurich, Zurich, Switzerland.
Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland.
Mol Psychiatry. 2014 May;19(5):625-32. doi: 10.1038/mp.2013.51. Epub 2013 Apr 30.
Long-lasting neuroadaptations in the glutamatergic corticostriatal circuitry have been suggested to be responsible for the persisting nature of drug addiction. In particular, animal models have linked the metabotropic glutamate receptor 5 (mGluR5) to drug-seeking behavior and extinction learning. Accordingly, blocking mGluR5s attenuated self-administration of cocaine and other addictive drugs in rats. How these animal findings extend to humans remains unclear. Therefore, we investigated if human cocaine users (CU) exhibit altered mGluR5 availability compared with drug-naïve control subjects. Seventeen male controls (11 smokers) and 18 male cocaine users (13 smokers) underwent positron emission tomography with (11)C-ABP688 to quantify mGluR5 availability in 12 volumes of interest in addiction-related brain areas. Drug use was assessed by self-report and quantitative hair toxicology. CU and controls did not significantly differ in regional mGluR5 availability. In contrast, smokers (n=24) showed significantly lower mGluR5 density throughout the brain (mean 20%) compared with non-smokers (n=11). In terms of effect sizes, lower mGluR5 availability was most pronounced in the caudate nucleus (d=1.50, 21%), insula (d=1.47, 20%), and putamen (d=1.46, 18%). Duration of smoking abstinence was positively associated with mGluR5 density in all brain regions of interest, indicating that lower mGluR5 availability was particularly pronounced in individuals who had smoked very recently. Specifically tobacco smoking was associated with lower mGluR5 availability in both CU and controls, while cocaine use was not linked to detectable mGluR5 alterations. These findings have important implications regarding the development of novel pharmacotherapies aimed at facilitating smoking cessation.
谷氨酸能皮质纹状体回路中的持久神经适应被认为是导致药物成瘾持续性的原因。特别是,动物模型将代谢型谷氨酸受体 5(mGluR5)与觅药行为和消退学习联系起来。因此,阻断 mGluR5 可减弱大鼠可卡因和其他成瘾药物的自我给药。这些动物研究结果如何扩展到人类尚不清楚。因此,我们研究了人类可卡因使用者(CU)与药物-naive 对照组相比是否表现出 mGluR5 可用性的改变。17 名男性对照者(11 名吸烟者)和 18 名男性可卡因使用者(13 名吸烟者)接受了 11C-ABP688 的正电子发射断层扫描,以量化成瘾相关脑区 12 个感兴趣区域的 mGluR5 可用性。通过自我报告和定量毛发毒理学评估药物使用情况。CU 和对照组在区域 mGluR5 可用性方面没有显着差异。相反,吸烟者(n=24)的整个大脑的 mGluR5 密度显着降低(平均 20%),而非吸烟者(n=11)。就效应大小而言,尾状核(d=1.50,21%)、岛叶(d=1.47,20%)和壳核(d=1.46,18%)中 mGluR5 可用性降低最为明显。吸烟禁欲时间与所有感兴趣脑区的 mGluR5 密度呈正相关,表明在最近吸烟的个体中,mGluR5 可用性降低更为明显。具体来说,吸烟与 CU 和对照组中 mGluR5 可用性降低均相关,而可卡因使用与可检测到的 mGluR5 改变无关。这些发现对于开发旨在促进戒烟的新型药物治疗具有重要意义。